The treatment and prognosis for feline mast cell tumors vary depending on the grade. We’ve compiled the essential information every pet owner should know in a Q&A format.



| Item | Malignancy | Main treatment | Recurrence probability |
|---|---|---|---|
| Group 1 (benign) | Low | Surgical excision | Low (some recurrence possible) |
| Group 2 (malignant) | High | Surgery + consider chemotherapy/targeted therapy if needed | Present (metastasis possible) |
Feline mast cell tumors are classified into two stages, Group 1 (benign) and Group 2 (malignant), based on mitotic count and cell morphology; surgery is the primary treatment, and most achieve long-term survival with surgery alone.

Seek Immediate Veterinary Care in These Cases
Seek immediate veterinary care if the tumor grows rapidly, the skin becomes red and swollen, or your cat persistently scratches and irritates the area. Additionally, a loss of appetite or repeated vomiting may indicate systemic symptoms related to the tumor, requiring professional evaluation. These signs could suggest a malignant (Group 2) tumor or progression to internal organs.

Points to Note During Treatment
Cats taking chemotherapy may experience side effects such as loss of appetite, vomiting, and diarrhea. Consult your veterinarian before administering the medication, and offering a simple change in diet can also help.

A veterinarian who majored in veterinary medicine at Khon Kaen University, Thailand, and completed the IVSA program at North Carolina State University in the United States. Drawing on clinical experience at animal hospitals, he works in the pet healthcare field and is dedicated to building a digital care environment that connects pet parents with veterinarians.
Share
[1] Hawkins E, et al. (2018) Feline mast cell tumors: diagnosis, grading, and treatment. Veterinary Clinics of North America: Small Animal Practice, 48(3), 487–504.
[2] Bergman PJ, et al. (2015) Prognostic factors in feline cutaneous mast cell tumors: a retrospective study of 128 cases. Journal of Veterinary Internal Medicine, 29(4), 1175–1181.